---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-249594"
form_type: "8-K"
ticker: "CATX"
cik: "0000728387"
company_name: "Perspective Therapeutics, Inc."
filed_at: "2026-06-01T10:30:22+00:00"
generated_at: "2026-06-01T10:35:36.508606+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Perspective Therapeutics updates pipeline: VMT-α-NET durable disease control; VMT01 and PSV359 progress

## Summary
- VMT-α-NET (SSTR2+ NET) Phase 1/2a shows durable disease control; potential registration study at current dose level.
- VMT01 (MC1R melanoma) Phase 1/2a: preliminary anti-tumor activity observed at 3.0 mCi dose.
- PSV359 (FAP-ɑ solid tumors) Phase 1/2a demonstrates improved tumor retention in ongoing trial.
- Integrated isotope production enables direct-to-hospital delivery and regional manufacturing for supply.

## SEC filing metadata
- accession: 0001193125-26-249594
- form_type: 8-K
- ticker: CATX
- cik: 0000728387
- company_name: Perspective Therapeutics, Inc.
- filed_at: 2026-06-01T10:30:22+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/728387/000119312526249594/0001193125-26-249594-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/728387/000119312526249594/catx-20260601.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-249594
- JSON: https://secwatch.observer/filing/0001193125-26-249594.json
- Plain text: https://secwatch.observer/filing/0001193125-26-249594.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.